On August 18, 2026, Anthropic announced it selected Twist Bioscience as an independent evaluator to rapidly produce at scale AI-designed proteins for a multi-arm campaign against 15 targets using Claude Opus 4.8 and Mythos Preview. This partnership involves testing designs for binding capabilities. The company operates in the synthetic biology industry, specializing in DNA synthesis and protein design.

Twist Bioscience Corporation priced an upsized public offering of 3,125,000 shares of common stock at $96.00 per share on August 4, 2026. The company granted underwriters a 30-day option to purchase up to an additional 468,750 shares, which was exercised in full the following day. Net proceeds from the offering are expected to be approximately $327.1 million after deducting underwriting discounts and estimated expenses. Funds will support research and development, manufacturing expansion, and working capital. Twist Bioscience Corporation operates in the biotechnology industry, providing customizable DNA synthesis solutions for diagnostics, therapeutics, and research markets.

Twist Bioscience Corporation reported fiscal third quarter 2026 financial results for the period ended June 30, 2026. The company achieved record revenue of $118.4 million, representing a 23% increase from $96.1 million in the prior year period and marking its fourteenth consecutive quarter of sequential growth. Gross margin improved to 52.8%, up 120 basis points sequentially. Management raised full-year fiscal 2026 revenue guidance to $456–$457 million, increasing the midpoint by $12 million, while reiterating expectations for fourth-quarter adjusted EBITDA breakeven. The company operates in the synthetic biology industry, providing DNA synthesis and next-generation sequencing applications.